Analyst Ranking
Bottom 8%
#4820 out of 5230 analysts
Average Return
-3.18%
Win Rate
40%36 out of 91
Risk vs Reward
Poor
Good

Paul Matteis's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Alto Neuroscience IncANRO
+213.47%$4.53$14.20
2024-11-13 -
2025-11-12
Strong Buy
Sionna Therapeutics IncSION
+130.34%$14.80$34.09
2025-03-04 -
2026-03-03
Strong Buy
Compass Pathways PLCCMPS
+86.99%$3.92$7.33
2025-02-27 -
2026-02-26
Strong Buy
Dyne Therapeutics IncDYN
+74.01%$9.85$17.14
2025-07-31 -
2026-03-27
Strong Buy
Rhythm Pharmaceuticals IncRYTM
+71.80%$52.97$91.00
2025-03-05 -
2026-03-04
Strong Buy

Paul Matteis's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Lb Pharmaceuticals IncLBRX
3Strong Buy$40.00+67.79%Maintains
3 days ago
Denali Therapeutics IncDNLI
4Strong Buy$41.00+125.77%Maintains
4 days ago
Kalvista Pharmaceuticals IncKALV
2Strong Buy$42.00+117.28%Maintains
4 days ago
Acadia Pharmaceuticals IncACAD
7Hold$24.00+15.66%Maintains
a month ago
Vertex Pharmaceuticals IncVRTX
16Hold$466.00+7.60%Maintains
a month ago
Uniqure NvQURE
3Strong Buy$40.00+170.82%Maintains
4 months ago
Neurocrine Biosciences IncNBIX
8Strong Buy$188.00+46.51%Maintains
4 months ago
Dyne Therapeutics IncDYN
5Strong Buy$39.00+127.54%Maintains
4 months ago
Alnylam Pharmaceuticals IncALNY
10Strong Buy$508.00+60.07%Maintains
4 months ago
Maplight Therapeutics IncMPLT
1Strong Buy$28.00+50.94%Initiates Coverage On
4 months ago
Neumora Therapeutics IncNMRA
3Hold$3.00+28.76%Maintains
4 months ago
Biomarin Pharmaceutical IncBMRN
11Hold$61.00+12.67%Downgrades
5 months ago
Biogen IncBIIB
7Strong Buy$202.00+9.88%Upgrades
5 months ago
Ionis Pharmaceuticals IncIONS
5Hold$67.00-7.14%Maintains
6 months ago
Pepgen IncPEPG
3Strong Buy$12.00+165.49%Maintains
6 months ago
Rhythm Pharmaceuticals IncRYTM
2Strong Buy$94.00+23.98%Maintains
10 months ago
Vigil Neuroscience IncVIGL
2Hold$8.00-0.62%Downgrades
10 months ago
Sionna Therapeutics IncSION
1Strong Buy$32.00N/AInitiates Coverage On
a year ago
Gh Research PLCGHRS
2Strong Buy$32.00N/AMaintains
a year ago
Compass Pathways PLCCMPS
1Strong Buy$11.00N/AInitiates Coverage On
a year ago
Sage Therapeutics IncSAGE
5Hold$6.00N/AMaintains
a year ago
Alector IncALEC
5Hold$4.00N/ADowngrades
a year ago
Alto Neuroscience IncANRO
3Strong Buy$10.00N/AMaintains
a year ago
Neurogene IncNGNE
2Strong Buy$60.00N/AMaintains
a year ago
Alkermes PLCALKS
5Strong Buy$36.00N/AUpgrades
a year ago
Rapport Therapeutics IncRAPP
1Strong Buy$35.00N/AInitiates Coverage On
2 years ago
Contineum Therapeutics IncCTNM
1Strong Buy$29.00N/AInitiates Coverage On
2 years ago
Lexeo Therapeutics IncLXEO
1Strong Buy$20.00N/AInitiates Coverage On
2 years ago
Vistagen Therapeutics IncVTGN
1Strong Buy$12.00N/AInitiates Coverage On
2 years ago
Karuna Therapeutics IncKRTX
3Strong Buy$295.00N/AMaintains
4 years ago
Cerevel Therapeutics Holdings IncCERE
2Strong Buy$54.00N/AMaintains
4 years ago
Leonabio IncLONA
2Hold$50.00N/ADowngrades
4 years ago
Climb Bio IncCLYM
1Strong Buy$35.00N/AInitiates Coverage On
5 years ago
Acumen Pharmaceuticals IncABOS
1Strong Buy$27.00N/AInitiates Coverage On
5 years ago
Prevail Therapeutics IncPRVL
1Strong Buy$23.00N/AInitiates Coverage On
6 years ago
Gw Pharmaceuticals PLCGWPH
4Hold$140.00N/ADowngrades
6 years ago
Avadel Pharmaceuticals PLCAVDL
1Strong Buy$14.00N/AInitiates Coverage On
6 years ago
Zogenix IncZGNX
3Buy$60.00N/AInitiates Coverage On
7 years ago
Acorda Therapeutics IncACORQ
1Hold$2,280.00N/AMaintains
7 years ago
Akcea Therapeutics IncAKCA
2Hold$31.00N/AMaintains
8 years ago
Obseva SaOBSVF
1Buy$18.00N/AMaintains
8 years ago
Wave Life Sciences LtdWVE
1Buy$64.00N/AMaintains
8 years ago
Cidara Therapeutics IncCDTX
1Buy$340.00N/AInitiates Coverage On
9 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.